[go: up one dir, main page]

IL151348A0 - Enhancement of antibody-mediated immune responses - Google Patents

Enhancement of antibody-mediated immune responses

Info

Publication number
IL151348A0
IL151348A0 IL15134801A IL15134801A IL151348A0 IL 151348 A0 IL151348 A0 IL 151348A0 IL 15134801 A IL15134801 A IL 15134801A IL 15134801 A IL15134801 A IL 15134801A IL 151348 A0 IL151348 A0 IL 151348A0
Authority
IL
Israel
Prior art keywords
enhancement
antibody
immune responses
mediated immune
mediated
Prior art date
Application number
IL15134801A
Other languages
English (en)
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of IL151348A0 publication Critical patent/IL151348A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15134801A 2000-04-13 2001-04-13 Enhancement of antibody-mediated immune responses IL151348A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19855000P 2000-04-13 2000-04-13
US20425400P 2000-05-15 2000-05-15
PCT/US2001/012106 WO2001079299A1 (en) 2000-04-13 2001-04-13 Enhancement of antibody-mediated immune responses

Publications (1)

Publication Number Publication Date
IL151348A0 true IL151348A0 (en) 2003-04-10

Family

ID=26893900

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15134801A IL151348A0 (en) 2000-04-13 2001-04-13 Enhancement of antibody-mediated immune responses
IL151348A IL151348A (en) 2000-04-13 2002-08-19 USE OF A THERAPEUTIC ANTIBODY WITH A MODIFIED Fc REGION TO PREPARE A PHARMACEUTICAL COMPOSITION WITH ENHANCED CYTOTOXICITY
IL218666A IL218666A (en) 2000-04-13 2012-03-15 Increase antibody-mediated immune responses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL151348A IL151348A (en) 2000-04-13 2002-08-19 USE OF A THERAPEUTIC ANTIBODY WITH A MODIFIED Fc REGION TO PREPARE A PHARMACEUTICAL COMPOSITION WITH ENHANCED CYTOTOXICITY
IL218666A IL218666A (en) 2000-04-13 2012-03-15 Increase antibody-mediated immune responses

Country Status (7)

Country Link
US (3) US7416726B2 (de)
EP (2) EP1272526A4 (de)
JP (1) JP2003531149A (de)
AU (3) AU5345901A (de)
CA (1) CA2399940A1 (de)
IL (3) IL151348A0 (de)
WO (1) WO2001079299A1 (de)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) * 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001240020B9 (en) 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
PT1265928E (pt) * 2000-01-27 2010-09-30 Medimmune Llc Anticorpos neutralizantes com afinidade ultra-elevada
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1355919B1 (de) * 2000-12-12 2010-11-24 MedImmune, LLC Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2436180C (en) * 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
ES2326964T3 (es) * 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) * 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
GB0225736D0 (en) * 2002-11-05 2002-12-11 Adjuvantix Ltd T-Cell Independent Vaccine
ES2897506T3 (es) * 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP5652987B2 (ja) * 2003-11-26 2015-01-14 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオＭａｘ−Ｐｌａｎｃｋ−Ｇｅｓｅｌｌｓｃｈａｆｔ ｚｕｒ Ｆｏｅｒｄｅｒｕｎｇ ｄｅｒ Ｗｉｓｓｅｎｓｃｈａｆｔｅｎ ｅ．Ｖ． ヒトＩｇＧＦｃレセプターＩＩｂ（ＦｃγＲＩＩｂ）に結合する物質
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
MXPA06011796A (es) * 2004-04-16 2007-05-07 Macrogenics Inc Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
KR101297146B1 (ko) * 2004-05-10 2013-08-21 마크로제닉스, 인크. 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
NZ553118A (en) * 2004-09-02 2009-12-24 Genentech Inc Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
KR101027427B1 (ko) 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP1835935A4 (de) * 2004-12-30 2009-06-17 Univ Rockefeller Zusammensetzungen und verfahren für die verbesserte dendritische zellreifung und funktion
EP1858925A2 (de) * 2005-01-12 2007-11-28 Xencor, Inc. Antikörper und fc-fusionsproteine mit veränderter immunogenizität
KR101289537B1 (ko) 2005-02-15 2013-07-31 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
EP1874816A4 (de) * 2005-04-26 2010-08-25 Medimmune Inc Modulation der antikörpereffektorfunktion mittels manipulation von verbindungsregionen
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
CA2614181A1 (en) * 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
PL1919503T3 (pl) * 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
EP1931709B1 (de) 2005-10-03 2016-12-07 Xencor, Inc. Fc-varianten mit optimierten rezeptorbindungseigenschaften
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
CA2625619A1 (en) 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
FR2894982A1 (fr) * 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1999470A4 (de) * 2006-03-10 2009-08-19 Macrogenics Inc Identifizierung und herstellung von antikörpern mit variierenden schweren ketten und anwendungsverfahren dafür
US7786270B2 (en) * 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2008022152A2 (en) 2006-08-14 2008-02-21 Xencor, Inc. Optimized antibodies that target cd19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US8580263B2 (en) * 2006-11-21 2013-11-12 The Regents Of The University Of California Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
US20080127996A1 (en) * 2006-12-04 2008-06-05 Weinhold Dennis G Method and apparatus to remediate an acid and/or liquid spill
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
RU2549701C2 (ru) 2007-05-07 2015-04-27 Медиммун, Ллк Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
ES2558689T3 (es) 2007-05-14 2016-02-08 Medimmune, Llc Métodos para reducir los niveles de eosinófilos
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
US20110077383A1 (en) * 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
WO2009081201A2 (en) 2007-12-21 2009-07-02 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Rα) - 173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP3825329A1 (de) 2007-12-26 2021-05-26 Xencor, Inc. Fc-varianten mit veränderter bindung zu fcrn
EP3067063A1 (de) 2008-04-02 2016-09-14 MacroGenics, Inc. Her2/neu-spezifische antikörper und verfahren zur verwendung davon
ES2654937T3 (es) 2008-04-02 2018-02-15 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
EP2111869A1 (de) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Zusammensetzungen und Verfahren zur Stärkung des Immunsystems
EP2282770B1 (de) * 2008-06-04 2018-03-07 MacroGenics, Inc. Antikörper mit veränderter bindung an fcrn und verwendungsverfahren dafür
CA2739429C (en) * 2008-10-14 2020-12-22 Lisa A. Damico Immunoglobulin variants and uses thereof
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
PL2486141T3 (pl) 2009-10-07 2018-07-31 Macrogenics, Inc. Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów
KR102092744B1 (ko) 2009-12-21 2020-03-24 리제너론 파마슈티칼스 인코포레이티드 인간화된 ＦｃγＲ 마우스
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2691417B2 (de) 2011-03-29 2024-10-30 Roche Glycart AG Antikörper-fc-varianten
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
MX361337B (es) 2012-07-13 2018-12-04 Roche Glycart Ag Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN107090041B (zh) 2013-09-13 2018-11-16 百济神州有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
AU2014383904B2 (en) 2014-02-21 2019-08-29 Avcatech Laboratories Pty Ltd Data communication device and method
TWI687438B (zh) 2014-07-03 2020-03-11 英屬開曼群島商百濟神州生物科技有限公司 抗ｐｄ-ｌ１抗體及其作為治療及診斷之用途
RU2711141C2 (ru) 2014-07-22 2020-01-15 СиБи ТЕРЕПЬЮТИКС, ИНК. Антитела против pd-1
CA2956399A1 (en) 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
IL262396B2 (en) 2016-04-15 2023-09-01 Macrogenics Inc New b7-h3 binding molecules, drug-antibody conjugates and their uses
NZ749997A (en) 2016-07-05 2022-11-25 Beigene Ltd Combination of a pd-l antagonist and a raf inhibitor for treating cancer
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
EP4353747A3 (de) 2016-08-19 2024-06-26 BeiGene Switzerland GmbH Kombination von zanubrutinib mit einem anti-cd20 oder einem anti-pd-1-antikörper zur verwendung bei der behandlung von krebs
CN110290810A (zh) 2016-12-13 2019-09-27 博尔特生物治疗药物有限公司 抗体佐剂缀合物
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3573989A4 (de) 2017-01-25 2020-11-18 Beigene, Ltd. Kristalline formen von (s)-7-(1-(but-2-ynoyl)-piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-carboxamid, herstellung und verwendungen davon
DK3609540T5 (da) 2017-04-14 2024-09-02 Bolt Biotherapeutics Inc Fremgangsmåde til immunkonjugatsyntese
JP2020525411A (ja) 2017-06-26 2020-08-27 ベイジーン リミテッド 肝細胞癌のための免疫療法
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CN108342404B (zh) * 2018-03-08 2021-06-25 国家卫生计生委科学技术研究所 Inpp5e基因突变体及其应用
KR20210013096A (ko) 2018-05-17 2021-02-03 볼트 바이오테라퓨틱스 인코퍼레이티드 면역접합체
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP2022513306A (ja) 2018-08-29 2022-02-07 ボルト バイオセラピューティクス、インコーポレーテッド Ｅｇｆｒを標的とする免疫結合体
WO2020190731A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020190760A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting cea
US20220226491A1 (en) 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting PD-L1
EP3937984A1 (de) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Gegen her2 gerichtete immunkonjugate
TW202112752A (zh) 2019-06-13 2021-04-01 美商博特生物治療公司 胺基苯并氮呯化合物、免疫接合物及其用途
CN114630684A (zh) 2019-09-03 2022-06-14 博尔特生物治疗药物有限公司 氨基喹啉化合物、免疫缀合物及其用途
CA3151662A1 (en) 2019-09-04 2021-03-11 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
AU2020359446A1 (en) 2019-09-30 2022-04-21 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
BR112022007719A2 (pt) 2019-10-25 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
US20230086603A1 (en) 2020-01-21 2023-03-23 Bolt Biotherapeutics, Inc Anti-pd-l1 antibodies
CN115175939A (zh) 2020-01-21 2022-10-11 博尔特生物治疗药物有限公司 抗pd-l1抗体
KR20220145871A (ko) 2020-02-25 2022-10-31 볼트 바이오테라퓨틱스 인코퍼레이티드 암 치료 방법
EP4142881A1 (de) 2020-05-01 2023-03-08 Bolt Biotherapeutics, Inc. Anti-dectin-2-antikörper
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CN116234586A (zh) 2020-08-13 2023-06-06 博尔特生物治疗药物有限公司 吡唑并氮呯免疫缀合物及其用途
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
CN116635084A (zh) 2020-12-11 2023-08-22 博尔特生物治疗药物有限公司 抗cea免疫缀合物和其用途
EP4259211A1 (de) 2020-12-11 2023-10-18 Bolt Biotherapeutics, Inc. Anti-her2-immunkonjugate und verwendungen davon
CA3200056A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-her2 immunoconjugates, and uses thereof
WO2022125908A1 (en) 2020-12-11 2022-06-16 Bolt Biotherapeutics, Inc. Anti-pd-l1 immunoconjugates, and uses thereof
AU2022245340A1 (en) 2021-03-26 2023-11-09 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CN117769439A (zh) 2021-03-26 2024-03-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
US20250000995A1 (en) 2021-10-29 2025-01-02 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2024130003A1 (en) 2022-12-15 2024-06-20 Bolt Biotherapeutics, Inc. Cancer combination treatment method
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
WO2024173384A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2024216089A1 (en) 2023-04-13 2024-10-17 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibody combination therapy
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4752601A (en) 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5792844A (en) 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5783682A (en) 1990-07-27 1998-07-21 Isis Pharmaceuticals, Inc. Oligonucleotide mimics having nitrogen-containing linkages
WO1992005263A1 (en) 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
US5364930A (en) 1990-10-16 1994-11-15 Northwestern University Synthetic C1q peptide fragments
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
WO1994008003A1 (en) 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
EP0714409A1 (de) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antikoerper
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5637687A (en) 1993-08-31 1997-06-10 Wiggins; James C. Methods and compositions for isolating nucleic acids
US5928900A (en) 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
EP0753069A1 (de) 1994-04-15 1997-01-15 Targeted Genetics Corporation Fusionsprotein für Gentransfer
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
US6028053A (en) * 1995-10-27 2000-02-22 Mount Sinai Hospital Corporation Peptide inhibitors of a phosphotyrosine-binding domain containing protein
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ES2300113T3 (es) 1996-08-02 2008-06-01 Bristol-Myers Squibb Company Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
PL337617A1 (en) 1997-06-30 2000-08-28 Rhone Poulenc Rorer Sa Apparatus for performing optimised in vivo electrotransfer of vectorial nucleic acids into tissues
ATE290403T1 (de) 1997-06-30 2005-03-15 Roussy Inst Gustave Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
JP2002505086A (ja) 1998-02-25 2002-02-19 レキシジェン ファーマシューティカルズ コーポレイション 抗体ベースの融合タンパク質の循環半減期の増強
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1109545A4 (de) 1998-09-11 2004-11-10 Ilexus Pty Ltd Fc REZEPTORMODULATOREN UND DEREN VERWENDUNGEN
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IL146872A0 (en) * 1999-06-03 2002-08-14 Methods and compositions for modulating cell proliferation and cell death
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
NZ571596A (en) * 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

Also Published As

Publication number Publication date
EP1272526A4 (de) 2004-10-13
CA2399940A1 (en) 2001-10-25
US20090060911A1 (en) 2009-03-05
AU5345901A (en) 2001-10-30
JP2003531149A (ja) 2003-10-21
US20110052584A1 (en) 2011-03-03
WO2001079299A1 (en) 2001-10-25
IL218666A (en) 2017-12-31
AU2007200851A1 (en) 2007-03-15
IL218666A0 (en) 2012-05-31
IL151348A (en) 2013-02-28
EP1272526A1 (de) 2003-01-08
US7416726B2 (en) 2008-08-26
EP2264072A1 (de) 2010-12-22
AU2010202377A1 (en) 2010-07-01
US20010036459A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
IL218666A (en) Increase antibody-mediated immune responses
HUP0204546A3 (en) Carbohydrate formulation for enhancement of immune response
HK1061403A1 (en) ANTIBODIES TO HUMAN IL-1ß
AU145943S (en) Bathtub
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
IL156276A0 (en) Induction of tolerance
EP1307211A4 (de) Immunmediatoren und verwandte methoden
AUPQ885500A0 (en) Enhancement of products
AU2002249917A1 (en) Induction of immune responses to isoaspartyl-modified antigens
EP1264600A4 (de) ZUSAMMENSETZUNGEN ZUR VERSTäRKUNG DER IMMUNITäT UND IHRE VERWENDUNG
GB9908263D0 (en) Eliciting improved immune responses
GB0014437D0 (en) Immune response stimulation
AU2001252907A1 (en) Superantigen enhancement of specific immune responses
AU2002364161A1 (en) Enhancement of the immune response using cd36-binding domain
GB0008265D0 (en) Specific immune milk
GB0019303D0 (en) Processed beverages
CA93196S (en) Bathtub
TW541924U (en) Improvement of assembly chopstick
GB0017139D0 (en) Human monoclonal antibodies
GB0112448D0 (en) Antigens
GB0119479D0 (en) Antigens
GB0026667D0 (en) Lipids promoting immune response
CA94230S (en) Combined tub and surround
GB0106966D0 (en) Improved expression of cartenoids
GB0127834D0 (en) Improved expression of cartenoids